

University of California, San Francisco  
Helen Diller Family Comprehensive Cancer Center

Policy for Clinical Trial SAE Reporting Outside of Business Hours

Table of Contents

Purpose ..... 1  
Scope ..... 1  
Background..... 1  
Procedures ..... 2  
    1.0 Initial Reports..... 2  
    2.0 Follow-Up Reports ..... 2  
Policy Exemptions..... 2  
References ..... 2  
Policy Approval ..... 3

**Purpose**

This policy defines the process for ensuring timely reporting of Serious Adverse Events (SAEs) occurring under externally sponsored clinical trials conducted at the Helen Diller Family Comprehensive Cancer Center (HDFCCC).

**Scope**

This policy applies to all interventional clinical trials conducted at the HDFCCC in which the clinical trial protocol mandates expedited (within 72 hours) SAE reporting to an external sponsor.

**Definitions**

*Business hours* – 9:00am - 5:00pm Pacific Time, Mondays through Fridays, except [holidays](#).

**Background**

FDA Investigational New Drug applications (INDs) and Investigational Device Exemptions (IDEs) require trial sponsors report serious human safety-related events and unanticipated problems to the FDA expeditiously. To ensure sponsors can meet FDA deadlines, clinical research protocols include expectations on the speed at which sites or investigators must report SAEs to the sponsor. At the HDFCCC, clinical research support staff (i.e., clinical research coordinators (CRCs)) are not available to assist with reporting outside of business hours.

## **Procedures**

### **1.0 Initial Reports**

In the event that a Principal Investigator (PI) 1) becomes aware of an SAE outside of business hours and 2) the discovery timing is such that a full submission with the help of clinical research support staff is impractical, the PI will contact the trial's medical monitor or primary study contact via email or phone, as per protocol specific reporting timelines (or 1 calendar day, whichever is longer) to alert the sponsor of the event. The message will contain de-identified safety details known to the investigator at the time of the report, including: specified subject (study assigned participant ID), a suspected drug (if any), the reporting source (if not the investigator themselves), SAE terms(s), date of SAE onsite, date of PI awareness, and a brief clinical description of the event, including a preliminary assessment of whether a reasonable possibility exists that the drug caused the event.

If the event is communicated via phone, the investigator should follow up the phone call with an email to document the phone call's occurrence. Within one business day or the time allowed in the protocol, whichever is longer, the study team will file a full report per the protocol and reporting portal requirements.

In the event the PI is unavailable (e.g. vacation), prior to their absence, they may delegate reporting to an appropriate sub-investigator. The delegated sub-investigator should have access to the appropriate sponsor contact information as described above.

### **2.0 Follow-Up Reports**

If a clinical trial investigator receives new information pertaining to a previously submitted SAE report (e.g., event end date) outside of business hours, the investigator and study team should make a concerted effort to report the new information within 10 business days of awareness.

If the new information qualifies as a new SAE (as per protocol) e.g., severity or seriousness of event changes, the procedures in section 1.0 apply.

## **Policy Exemptions**

None

## **References**


[21 CFR 312 - INDs](#)

[21 CFR 812 - IDEs](#)


[UCSF Holiday Schedule](#)

## Policy Approval


This policy document was approved by the following personnel on the following dates:

DocuSigned by:  
  
E870F084A6CA4CC...  
Rahul Aggarwal, MD  
Acting Medical Director, Clinical Research Support Office  
Associate Director, Clinical Sciences  
Helen Diller Family Comprehensive Cancer Center

6/11/2024  
Date

DocuSigned by:  
  
7ECB32D327E3438...  
Eric Small, MD  
Deputy Director  
Helen Diller Family Comprehensive Cancer Center

6/14/2024  
Date

DocuSigned by:  
  
80D28169E90D41B...  
Kate Shumate, MPA  
Director, Administration and Planning  
Helen Diller Family Comprehensive Cancer Center

6/11/2024  
Date

Policy contact:  
Andrea Skafel, Clinical Research Support Office Director  
[Andrea.Skafel@ucsf.edu](mailto:Andrea.Skafel@ucsf.edu); +1 415 502 5805

**Certificate Of Completion**

Envelope Id: 3E270ADA0CFD42DCBC965E84B3C09A62	Status: Completed
Subject: Complete with DocuSign: Clin_Rsch_Policy_SAE business hours_V1_2024JUN11.pdf	
Source Envelope:	
Document Pages: 3	Signatures: 3
Certificate Pages: 2	Initials: 0
AutoNav: Enabled	Envelope Originator:
Enveloped Stamping: Disabled	Andrea Skafel
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	1855 Folsom St
	Suite 601
	San Francisco, CA 94103
	andrea.skafel@ucsf.edu
	IP Address: 128.218.42.98

**Record Tracking**

Status: Original	Holder: Andrea Skafel	Location: DocuSign
6/11/2024 9:49:03 AM	andrea.skafel@ucsf.edu	


**Signer Events**

Signer Events	Signature	Timestamp
eric small eric.small@ucsf.edu Professor University of California, San Francisco Security Level: Email, Account Authentication (Optional)	<p>DocuSigned by:</p>  <p>7FCB32D327E3438...</p> <p>Signature Adoption: Pre-selected Style Using IP Address: 128.218.42.232</p>	<p>Sent: 6/11/2024 9:50:32 AM Viewed: 6/14/2024 1:14:47 PM Signed: 6/14/2024 1:14:55 PM</p>

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

Katherine Shumate kate.shumate@ucsf.edu Chief of Staff, Director of Administration University of California, San Francisco Security Level: Email, Account Authentication (Optional)	<p>DocuSigned by:</p>  <p>80D38159E89D41B...</p> <p>Signature Adoption: Uploaded Signature Image Using IP Address: 128.218.42.65</p>	<p>Sent: 6/11/2024 9:50:32 AM Viewed: 6/11/2024 12:27:17 PM Signed: 6/11/2024 12:27:25 PM</p>
---	---	---

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

Rahul Aggarwal rahul.aggarwal@ucsf.edu Rahul Aggarwal, MD Professor of Medicine University of California, San Francisco Security Level: Email, Account Authentication (Optional)	<p>DocuSigned by:</p>  <p>E870F084A5CA4CC...</p> <p>Signature Adoption: Pre-selected Style Using IP Address: 64.54.15.151</p>	<p>Sent: 6/11/2024 9:50:33 AM Viewed: 6/11/2024 9:51:26 AM Signed: 6/11/2024 9:51:31 AM</p>
--	--	---

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp

<b>Witness Events</b>	<b>Signature</b>	<b>Timestamp</b>
-----------------------	------------------	------------------

<b>Notary Events</b>	<b>Signature</b>	<b>Timestamp</b>
----------------------	------------------	------------------

<b>Envelope Summary Events</b>	<b>Status</b>	<b>Timestamps</b>
--------------------------------	---------------	-------------------

Envelope Sent	Hashed/Encrypted	6/11/2024 9:50:33 AM
Certified Delivered	Security Checked	6/11/2024 9:51:26 AM
Signing Complete	Security Checked	6/11/2024 9:51:31 AM
Completed	Security Checked	6/14/2024 1:14:55 PM

<b>Payment Events</b>	<b>Status</b>	<b>Timestamps</b>
-----------------------	---------------	-------------------